Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRP antibody titer after Haemophilus influenzae type b conjugate vaccine
jRCT1080223268
- Sponsor
- The Chemo-Sero-Therapeutic Research Institute
- Start
- Jul 2016
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of Haemophilus b conjugate vaccine in Haemophilus influenzae type b disease (Hib), sponsored by The Chemo-Sero-Therapeutic Research Institute. Primary endpoint: PRP antibody titer after vaccination.
02
Drugs
Haemophilus b conjugate vaccine
03
Conditions
Haemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on jRCT1080223268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223268.